Also known as: RemeGen
RemeGen is a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative biologics for autoimmune diseases, oncology, and ophthalmology. The company has built a broad pipeline of first-in-class and best-in-class biologic drugs.
Biopharma companies face a $275b patent cliff as licensing activity shifts toward China. China represented almost half of 2025 licensing activity and contributes about 30% of the global biotech pipeline.
China’s cross-border biotech outlicensing hit US$60 billion in the first quarter of 2026. AbbVie’s up to $745 million Haisco pain deal highlights multinationals’ rising interest in Chinese drug assets.
AbbVie has successfully transitioned from Humira dependence to growth driven by Skyrizi and Rinvoq, while maintaining a 54-year dividend increase streak and expanding its pipeline to roughly 90 programs through strategic acquisitions.
Global pharmaceutical companies are accelerating licensing deals for China-developed experimental medicines, with deal values reaching unprecedented levels in 2026 as firms cut costs ahead of patent expirations.
